Condition: Diffuse Large B Cell Lymphoma (DLBCL) · High Grade B Cell Lymphoma · Sponsor: Memorial Sloan Kettering Cancer Center
The researchers are doing this study to find out if the study treatment is an effective treatment that causes few or mild side effects in people with diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), or transformed lymphoma. The treatment being tested in this study is glofitamab, polatuzumab, and obinutuzumab in combination with standard treatment (the combination of rituximab, cyclophosphamide, doxorubicin, and prednisone, or R-miniCHP).
This description comes directly from the study's public registry record.
Pallawi Torka, MD · 201-775-7808 · torkap@mskcc.org
Paul Hamlin, MD · 646-608-3706
Always discuss trial participation with your own doctor first.
| Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) | Basking Ridge, New Jersey, United States | Recruiting |
| Hackensack Meridian Health (Data collection only) | Hackensack, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities) | Commack, New York, United States | Recruiting |
| Memorial Sloan Kettering Westchester (All Protocol Activities) | Harrison, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Rockville Centre, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06765317